



Telix Pharmaceuticals Limited

ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Telix Completes Acquisition of Lightpoint Medical

Melbourne (Australia) – 1 November 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, today announces the completion of the acquisition of Lightpoint Medical and its SENSEI[®] radio-guided surgery business (refer to announcement on 21 June 2023).

Lightpoint Medical – a technology leader in precision-guided robotic cancer surgery – develops and markets miniaturised imaging and sensing tools for advanced intra-operative cancer detection. The acquisition will support and expand Telix’s late-stage urologic pipeline and, together with its complementary artificial intelligence technologies, will strengthen Telix’s capabilities in deploying molecular imaging in the surgical setting.

The initial commercial objective is to align SENSEI with Telix’s Illuccix[®]/TLX599-CDx¹ programs for prostate cancer. Additionally, there is considerable scope to expand the use of SENSEI and explore advanced surgical radiation detection probes in other urologic and non-urologic malignancies, including TLX250-CDx, Telix’s investigational kidney cancer imaging agent.

The upfront consideration value is US\$20.0 million (approximately AU\$30.6 million²), of which US\$19.6 million has been paid to Lightpoint Medical Limited in equity through the issue of 3,298,073 fully paid ordinary Telix shares at AU\$9.3659 per share, with the balance paid in cash. A further US\$15.0 million (approximately AU\$23.6 million³) is payable via an earn-out in the form of rights (Performance Rights). Performance Rights will be settled in cash or equity (at Telix’s election) upon achievement of certain milestones (Milestone Events) relating to the ongoing development and commercialisation of the SENSEI probe.⁴ Both upfront and any earnout equity will be subject to voluntary escrow conditions.⁵

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “The acquisition of Lightpoint Medical and its highly talented medtech team brings a compelling commercial-stage approved product to support and enhance Telix’s capabilities in deploying molecular imaging in the surgical setting. This strategic acquisition is in close alignment with our vision to innovate and partner with physicians at every step of the patient journey, with an initial focus on urology.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX:TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [LinkedIn](#).

¹ ^{99m}Tc-HYNIC-iPSMA.

² AUD/USD exchange rate of 0.6346.

³ AUD/USD exchange rate of 0.6346.

⁴ Refer Telix ASX disclosure 21 June 2023.

⁵ Refer Telix ASX Appendix 3B 21 June 2023.

Telix's lead product, gallium-68 (⁶⁸Ga) gozetotide (also known as ⁶⁸Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),⁶ by the Australian Therapeutic Goods Administration (TGA),⁷ and by Health Canada.⁸ Telix is also progressing Marketing Authorisation Applications for ⁶⁸Ga-PSMA-11 in the United Kingdom, the European Union⁹ and Brazil.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

⁶ Telix ASX disclosure 20 December 2021.

⁷ Telix ASX disclosure 2 November 2021.

⁸ Telix ASX disclosure 14 October 2022.

⁹ Telix ASX disclosure 3 April 2023.